Meta-analysis of interaction terms stratified by type of treatment

Author	logHR logHR (SE) 95% CI	Hazard ratio		Weight (fixed)	Weight (random)
Subgroup Treatment = PRIME PEAK 20050181 AIO KRK0104 CAIRO-3 Fixed effect model Random effects mode Heterogeneity: $\tau^2 = 0.0355$	0.30 0.273 0.18 0.884 0.87 0.285 0.60 0.363 -0.16 0.380	nti–EGFR 2 [0.79; 2.31] 9 [0.21; 6.78] 5 [1.37; 4.19] 7 [0.90; 3.73] 7 [0.41; 1.80] [1.15; 2.12] [1.08; 2.20]		1.35 - 1.20 2.39 1.83 0.85 1.56 1.54	12.3% 1.2% 11.3% 6.9% 6.3% 38.0%	12.3% 1.2% 11.3% 6.9% 6.3%
Subgroup Treatment = PEAK TRIBE AIO KRK0207 Fixed effect model Random effects mode Heterogeneity: $\tau^2 = 0$, $\chi_2^2 = 0$	0.02 1.092 0.37 0.312 0.39 0.207	nti-VEGF 2 [0.12; 8.69] 5 [0.78; 2.67] 1 [0.98; 2.21] [1.04; 2.03] [1.04; 2.03]		1.02 1.45 1.47 1.45 1.45	0.8% 9.4% 21.4% 31.6%	0.8% 9.4% 21.4% 31.6%
Subgroup Treatment = PRIME 20050181 Fixed effect model Random effects mode Heterogeneity: $\tau^2 = 0$, $\chi_1^2 = 0$	0.15 0.205 0.03 0.443	ne 7 [0.78; 1.74] 1 [0.43; 2.46] [0.79; 1.64] [0.79; 1.64]		1.17 1.03 1.14 1.14	4.7%	21.7% 4.7% 26.4%
Subgroup Treatment = OPTIMOX3 DREAM Fixed effect model Random effects mode Heterogeneity: not applica	-0.03 0.474	3 [0.38; 2.47] [0.38; 2.47] [0.38; 2.47]		0.97 0.97 0.97	4.1% 4.1% 	4.1% 4.1%
Fixed effect model Random effects mode Prediction interval Heterogeneity: $\tau^2 = 0$, χ^2_{10} Residual heterogeneity: χ^2	= 7.77 (p = 0.65)	[1.14; 1.66] [1.14; 1.66] [1.11; 1.71]	0.2 0.5 1 2 5	1.38 1.38	100.0% 	100.0%